Martin Little
A5031288050- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Growth Hormone and Insulin-like Growth Factors
- COVID-19 and healthcare impacts
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Cancer, Lipids, and Metabolism
- Healthcare cost, quality, practices
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
- Cancer survivorship and care
- Inflammatory Biomarkers in Disease Prognosis
- Advanced Breast Cancer Therapies
- Frailty in Older Adults
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac, Anesthesia and Surgical Outcomes
- Vaccine Coverage and Hesitancy
- Ferroptosis and cancer prognosis
- Cytomegalovirus and herpesvirus research
- Family Support in Illness
- American Literature and Humor Studies
- IgG4-Related and Inflammatory Diseases
Oxford University Hospitals NHS Trust
2021-2025
University of Oxford
2023-2025
John Radcliffe Hospital
2025
MRC Weatherall Institute of Molecular Medicine
2024
The Christie NHS Foundation Trust
2020-2023
Churchill Hospital
2022-2023
University of Manchester
2021
The Christie Hospital
2021
University of South Carolina
2021
Norfolk and Norwich University Hospital
2011
People with cancer are at increased risk of hospitalisation and death following infection SARS-CoV-2. Therefore, we aimed to conduct one the first evaluations vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients a population level.
PurposePeople living with cancer and haematological malignancies are at an increased risk of hospitalisation death following infection acute respiratory syndrome coronavirus 2. Coronavirus third dose vaccine boosters proposed to boost waning immune responses in immunocompromised individuals increase protection; however, their effectiveness has not yet been systematically evaluated.MethodsThis study is a population-scale real-world evaluation the United Kingdom's booster programme for...
Abstract Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients since 2020 has not previously been described. We therefore evaluated on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates hospital assessment(s), intensive care admission mortality. observed that disease become less non-cancer population....
Importance Accurate identification of patient groups with the lowest level protection following COVID-19 vaccination is important to better target resources and interventions for most vulnerable populations. It not known whether SARS-CoV-2 antibody testing has clinical utility high-risk groups, such as people cancer. Objective To evaluate spike protein vaccine response (COV-S) associated risk breakthrough infection or hospitalization among patients Design, Setting, Participants This was a...
Abstract Vaccines have revolutionised the field of medicine, eradicating and controlling many diseases. Recent pandemic vaccine successes highlighted accelerated pace development deployment. Leveraging this momentum, attention has shifted to cancer vaccines personalised vaccines, aimed at targeting individual tumour-specific abnormalities. The UK, now regarded for its capabilities, is an ideal nation pioneering trials. This article convened experts share insights approaches navigate...
SARS-CoV-2 continues to spread across the world as a highly transmissible endemic disease. For many cancer patients, infection is unavoidable. It disrupt care, causing treatment delays and major psycho-socio-medical issues. At present, there limited evidence on safe prescribing of anti-cancer therapy, restart following infection. We conducted prospective cohort study involving 406 COVID-19-positive patients five UK centres collected data delay durations, COVID-19 symptoms mortality,...
Abstract Background: Preclinical experiments in-vitro show MEK inhibitors can cause upregulation of p-FAK in KRASM cells. The combination a and FAK inhibitor could overcome this in-vivo. Methods: We are conducting an open label phase I dose escalation with expansion study (NCT03875820). Dose evaluated twice week schedule (Mon/Thurs) CH5126766/VS-6766 (CH) 3 weeks out 4 day dosing defactinib (Def) administered 4. levels explored were cohort 1 (CH 3.2 mg, 200 mg Def), 2a Def mg) 2b 400 mg)....
Abstract Purpose: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus selectively taken up by α-FR–overexpressing tumors. Patients Methods: A 3+3 dose escalation design was used. During escalation, doses of 1–6 mg/m2 weekly 2–12 every 2 weeks (q2Wk) intravenously were evaluated. with high-grade serous ovarian cancer enrolled in the expansion cohorts. Results: 109 patients enrolled: 42 67 At dose/schedule 12 mg/m2/q2Wk (with without...
Abstract Background KRAS is a known oncogenic driver in non-small cell lung cancer (NSCLC), with G12C and G12V mutations occurring ~13% ~7% of the NSCLC ( adenocarcinoma subtype). The dual RAF-MEK inhibitor VS-6766 has shown single agent activity against mutated (Guo C et al Lancet Oncology 2020, 21:1478-88). Based on pre-clinical data, we hypothesised that augmented focal adhesion kinase (FAK) signalling mechanism resistance to MEK inhibition devised current clinical trial. We have...
<h3>Introduction</h3> There are plausible mechanisms that carcinogenesis may be altered by: aspirin, NSAIDs, calcium-channel blockers and statins, through both inhibition of cyclo-oxygenase enzymes the production mediators cell cycle. The current epidemiological data in this area is either limited, reports conflicting results or does not consider important confounders. aim study was to investigate whether there a negative association between these medications development pancreatic cancer...
ABSTRACT Clinical responses to immune checkpoint blockade (ICB) for metastatic melanoma (MM) are variable, with patients frequently developing related adverse events (irAEs). The role played by myeloid populations in modulating ICB remains poorly defined. We explored the effect of MM and response across a cohort (n=116) healthy donors (n=45) using bulk single cell RNA-seq, flow cytometry. Monocytes from exhibit highly dysregulated baseline transcriptional profiles, whilst treatment elicits...
Summary Paragraph The relationship between chronic viral infection and cancer response to immune checkpoint blockade (ICB) is poorly understood. Cytomegalovirus (CMV) globally endemic causes severe disease in the immunocompromised. In immunocompetent individuals clinical effects of CMV are an area active investigation. Here, analysis 396 patients receiving ICB for cancer, we investigate oncological immunological consequences seropositivity. We find that with leads profound skewing CD8 + T...
Abstract CD8 + T cells play a central role in the cancer response to immune checkpoint blockade (ICB) treatment, with activity predicated upon antigen recognition by associated cell receptor (TCR) repertoire. The contribution of genetic variation this treatment is under-explored. We have conducted genome-wide and human leukocyte (HLA)-focused analysis TCR repertoire identify determinants variable gene (V-gene) CDR3 K-mer usage from samples taken prior after ICB (n=250). find 11 significant...
older patients represent the majority of cancer but are under-represented in trials, particularly early phase clinical trials (EPCTs).observational retrospective study referred for EPCTs (January-December 2018) at a specialist centre UK. The primary aim was to analyse successful enrolment into according age (<65/65+). secondary aims were identify obstacles and outcomes enrolled patients. Patient data analysed at: referral; in-clinic assessment after enrolment. Among assessed clinic, sample...